| |
著者: S Camara, J P de la Cruz, M A Frutos, P Sanchez, E Lopez de Novales, E Sanchez, F Sanchez de la Cuesta
雑誌名: Nephron. 1991;58(1):13-6.
Abstract/Text
The aim of the present study is to evaluate the effect of dipyridamole (300 mg/day) versus placebo in a double-blind randomized trial on membranous glomerulonephritis (M-GMN), mesangial IgA glomerulonephritis (IgA-GMN), and segmentary and focal hyalinosis glomerulonephritis (SFH-GMN) during the first 3 months of treatment. In the case of M-GMN, proteinuria dropped by 60% of the basal value in patients treated with dipyridamole; in the case of IgA-GMN it dropped by 65-70%; and in the case of SFH-GMN it dropped by 40% of the basal value. Inhibition of proteinuria in M-GMN was correlated to platelet response, and above all, to the ADP-induced platelet aggregation in whole blood.
PMID 1857478 Nephron. 1991;58(1):13-6.
|
